Oncotarget

Research Papers:

Analytical validation of NeXT Personal®, an ultra-sensitive personalized circulating tumor DNA assay

Josette Northcott, Gabor Bartha, Jason Harris, Conan Li, Fabio C.P. Navarro, Rachel Marty Pyke, Manqing Hong, Qi Zhang, Shuyuan Ma, Tina X. Chen, Janet Lai, Nitin Udar, Juan-Sebastian Saldivar, Erin Ayash, Joshua Anderson, Jiang Li, Tiange Cui, Tu Le, Ruthie Chow, Randy Jerel Velasco, Chris Mallo, Rose Santiago, Robert C. Bruce, Laurie J. Goodman, Yi Chen, Dan Norton, Richard O. Chen and John M. Lyle _

PDF  |  Full Text  |  Supplementary Files  |  How to cite  |  Press Release

Oncotarget. 2024; 15:200-218. https://doi.org/10.18632/oncotarget.28565

Metrics: PDF 445 views  |   Full Text 3109 views  |   ?  


Abstract

Josette Northcott1, Gabor Bartha1, Jason Harris1, Conan Li1, Fabio C.P. Navarro1, Rachel Marty Pyke1, Manqing Hong1, Qi Zhang1, Shuyuan Ma1, Tina X. Chen1, Janet Lai1, Nitin Udar1, Juan-Sebastian Saldivar1, Erin Ayash1, Joshua Anderson1, Jiang Li1, Tiange Cui1, Tu Le1, Ruthie Chow1, Randy Jerel Velasco1, Chris Mallo1, Rose Santiago1, Robert C. Bruce1, Laurie J. Goodman1, Yi Chen1, Dan Norton1, Richard O. Chen1,* and John M. Lyle1,*

1 Personalis, Inc., Fremont, CA 94555, USA

* Co-last authors

Correspondence to:

John M. Lyle, email: [email protected]

Keywords: circulating tumor DNA; whole genome sequencing; molecular residual disease; tumor-informed assay; analytical validation

Received: December 11, 2023     Accepted: February 12, 2024     Published: March 14, 2024

Copyright: © 2024 Northcott et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

We describe the analytical validation of NeXT Personal®, an ultra-sensitive, tumor-informed circulating tumor DNA (ctDNA) assay for detecting residual disease, monitoring therapy response, and detecting recurrence in patients diagnosed with solid tumor cancers. NeXT Personal uses whole genome sequencing of tumor and matched normal samples combined with advanced analytics to accurately identify up to ~1,800 somatic variants specific to the patient’s tumor. A personalized panel is created, targeting these variants and then used to sequence cell-free DNA extracted from patient plasma samples for ultra-sensitive detection of ctDNA.

The NeXT Personal analytical validation is based on panels designed from tumor and matched normal samples from two cell lines, and from 123 patients across nine cancer types. Analytical measurements demonstrated a detection threshold of 1.67 parts per million (PPM) with a limit of detection at 95% (LOD95) of 3.45 PPM. NeXT Personal showed linearity over a range of 0.8 to 300,000 PPM (Pearson correlation coefficient = 0.9998). Precision varied from a coefficient of variation of 12.8% to 3.6% over a range of 25 to 25,000 PPM. The assay targets 99.9% specificity, with this validation study measuring 100% specificity and in silico methods giving us a confidence interval of 99.92 to 100%.

In summary, this study demonstrates NeXT Personal as an ultra-sensitive, highly quantitative and robust ctDNA assay that can be used to detect residual disease, monitor treatment response, and detect recurrence in patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28565